Valeant gets additional notices of default from bondholders

Go back to Valeant gets additional notices of default from bondholders

Valeant Pharma (VRX) Appoints Joseph Papa as CEO

April 25, 2016 8:38 AM UTC

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer. Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a... More

Valeant Pharma (VRX) Announces Receipt of Additional Notice of Default Due to Delay of 10-K Filing

April 25, 2016 6:28 AM UTC

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that, as a result of the delay in the Company filing its Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K"), it has received notices of default from the trustee under the indentures governing its 5.375% Senior Notes due... More